Co-Chairs

Mr. Edward Wang
Board of Directors, TAITA-SV

CHIH-CHENG YEH

DIRECTOR
SCIENCE AND TECHNOLOGY DIV,
TAIPEI ECONOMIC AND CULTURAL OFFICE
IN SAN FRANCISCO

Mr. Chih-cheng Yeh received his first MS degree in Mechanical Engineering, National Central University, Taiwan, in 1990. He started his career as an Associate Engineer at the Metal Industrial Research and Development Center(MIRDC) (1992-1993); then, served for National Science Council as a program manager (1996-2001). In 1999, he won a full scholarship from British Council, UK, then received his second MS degree in Space Engineering, Cranfield University, UK in 2000. From 2001 to 2004, he was the Science & Technology Officer for Science and Technology Division, Taipei Economic and Cultural Office in San Francisco. With three-year overseas experience, he was recruited to the Ministry of Economic Affairs as the Minister Mei-Yueh Ho’s Special Assistant (2004-2006). In 2006-2010, Mr. Yeh was promoted to be the Section Chief, Deputy Director of Industrial Development Bureau(IDB), Ministry of Economic Affairs. During this period, he had been responsible for aeronautics, vehicle, and shipbuilding industries’ development. He also attended the negotiation of Early Harvest List, Economic Cooperation Framework Agreement(ECFA), with China. With six years industrial development experience, he returned to the National Science Council as Deputy Director General, then Director General to in charge of Science and Technology Planning (2010-2016). With his industrial development and R/D management experience, he has been appointed to take the position as the Director to the Science and Technology Division, Taipei Economic and Cultural Office in San Francisco, also know as the liaison office for Ministry of Science and Technology, Taiwan, in San Francisco.

EDWARD  WANG

BOARD OF DIRECTOR, TAITA-SV

 BIOGRAPHY:

Edward Wang is currently working at Roku as senior product manager for Roku TV responsible for launching new platforms in international markets.  Prior to joining Roku, he led new product and technology initiatives in major U.S., European and Asian companies in the area of wireless communication and digital media technology.  Edward has been actively participating in the TAITA events as board director and supporting initiatives to bridge both U.S. and Taiwan tech industry.  He has received his Executive MBA from University of Southern California, MSEE from University of Arizona and BSEE from University of Illinois at Urbana-Champaign.

TOPIC: How the Impact of COVID on Innovation in Life Science?

ALLAN W.MAY, J.D.

(AMAY@LIFESCIENCEANGELS.COM)

BIOGRAPHY:

Allan is a founder of Life Science Angels (www.lifescienceangels.org),the largest and most well-known early-stage investment group focused solely on emerging biotech, genomic, medical device, diagnostic and mobile health companies (LSA). LSA has invested over $70M in 65 portfolio companies and achieved 23 positive exits to dayte.  was named the Top Angel Investment Group in the United States by industry analytical source CB Insights(https://www.cbinsights.com/blog/top-angel-groups-mosaic/). In 2018, Allan co-founded Woodside China Medical, a Suzhou China based incubator helping commercialize U.S. medical technologies in China.

Allan was Managing Partner of Emergent MedicalPartners Venture Fund, andhas been founder, Chairman, CEO, or investor in over 100medtech, biotech, and diagnostic startups.He was a co-founder and Chairman of Nanostim, developer of a Leadless Cardiac pacemaker, which was acquired by St. Jude Medical in 2013, and co-founder and Chairman of Hyalex Surgical, Inc, developer of a novel artificial cartilage for total joint replacements.

Allan developed the medical device curriculum for Steve Blank’s inaugural groundbreaking Lean LaunchPad™program that is now taught at the National Institutes of Health and by the National Science Foundation as a core curriculum (i-Corps) for entrepreneurs.  Allan is a past member of the boards of directors of both the Kauffman Foundation’s Angel Capital Association and Angel Resource Institute, where he also served as Chairman.

TOPIC: Software Automation in Healthcare

Yan Chow, M.D., MBA

https://www.linkedin.com/in/yanchow/

Abstract:

Healthcare has undergone tremendous disruption in the last two years that has highlighted some of the structural weaknesses in the industry. This presentation will discuss some of the lessons learned, and why healthcare organizations are accelerating their plans for digital transformation, beginning with robotic process automation (RPA).

Biography:

Yan Chow, MD, MBA is the Global Healthcare Industry Lead at Automation Anywhere. Previously, he was Medical Director for Digital Medicine at Amgen, the world’s largest independent biotechnology company, where he led efforts to incorporate digital technologies and advanced analytics into clinical trials. He was also Chief Innovation Officer at LongView International Technology Solutions in Reston, VA, where he introduced new technologies to the VA and DoD.

Dr. Chow was the national Director of the Innovation & Advanced Technology Group (IAT) at Kaiser Permanente, the largest private integrated care delivery system in the nation. During his tenure, IAT assessed over 2,000 emerging technologies and operated a multi-million dollar innovation grant program for employees. IAT worked with KP’s Garfield Innovation Center, an award-winning care delivery simulation laboratory.

Dr. Chow has founded and advised a number of startups, including a venture-funded NLP analytics startup. He has 3 U.S. patents and has been an invited speaker at industry conferences. He was selected by Healthcare IT News (HIMSS) as one of three winners in the Innovator category of the 2014 H.I.T. Men & Women Awards, which recognize the top nine U.S. healthcare IT executives of the year.

Dr. Chow earned his A.B. with honors from Harvard University and his M.D. from UC San Diego. In 2005 he received his MBA as valedictorian from UC Berkeley’s Haas Business School.

TOPIC : Business Strategies after COVID

Ron Chiarello, Ph.D.

Founder and CEO at Alveo Technologies

Biography:

Ron Chiarello, Ph.D. has devoted nearly three decades of his career designing, developing and manufacturing cutting-edge micro-fluidic, micro-electronics and semiconductor technologies. He founded Alveo Technologies in 2015 to develop innovative healthcare solutions that empower individuals around knowing their own health. Alveo recently won the $6M XPRIZE Rapid COVID Testing Competition for its be.well™ COVID-19 Test, an at-home infectious disease test initially focused on upper respiratory infections that can be adapted to detect a wide range of infectious diseases, saving countless lives and medical resources globally.

Prior to founding Alveo Technologies in 2015, Dr. Chiarello co-founded Jetalon Solutions in 2002, where he led the development and commercial deployment of Jetalon’s sensor solutions to micro-electronic, biopharmaceutical, petrochemical, and solar cell manufacturers worldwide. In 2013 Jetalon was acquired by Entegris. He also founded and sold Etalon Technologies (1997-2002) and Orion Metrology (2007-2010).

Dr. Chiarello earned his Bachelor of Science in Physics at the University of California Santa Barbara and his Doctor of Philosophy (Ph.D.) in Physics from Northeastern University. Dr. Chiarello has spent more than a decade in research and development working with institutions like Argonne National Laboratory, the University of Chicago, and Stanford University, where he functioned as a program director for a number of years. A NATO fellow, he has 43 patents and patents pending in 14 countries, published more than 50 technical articles and has been a recipient of the Department of Energy Award for Excellence in Research and the University of Chicago’s Pace Setter Award.

Topic: The Future of Digital Surveillance and Connected Care – Lessons from the COVID-19 Pandemic

Jason Wang, MD, PhD

Director, Center for Policy, Outcomes and Prevention, Associate Professor of Pediatrics (General Pediatrics) and Health Policy Stanford University

Biography:

Jason Wang, MD, PhD, is Director of the Center for Policy, Outcomes, and Prevention, and Associate Professor of Pediatrics and Medicine at Stanford University. He also co-chairs the mobile health and other new technologies group at the Stanford Center for Population Health Sciences.  He received his B.S. from MIT, Medical Doctorate from Harvard Medical School, and Ph.D. in policy analysis from RAND.  After completing his pediatric residency training at UCSF, he worked in Greater China with McKinsey and Company. In 2000, he was recruited to serve as the project manager for Taiwan’s Healthcare Reform Taskforce. Among his honors, he was selected as the student speaker for the Harvard Medical School commencement ceremony in 1996, a recipient of the 2011 NIH Director’s New Innovator Award, and an invited speaker for Johns Hopkins University Bloomberg School of Public Health 100th Year, Child Health Policy Symposium.

His recent work on COVID-19 includes: 1) “Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing” published in JAMA, which has been viewed over 1 million times online (ranked top 3 most viewed JAMA article in 2020) and covered by 273 media outlets world-wide; 2) “Ethics and Governance of Digital disease Surveillance”, published in Science; 3) “How Community and Unity Can Help Americans Survive”, published in Journal of General Internal Medicine; 4) “How to Prevent and Manage Hospital-Based Infections During Coronavirus Outbreaks: Five Lessons from Taiwan”, published in Journal of Hospital Medicine; 5) “How to Safely Reopen Colleges and Universities During COVID-19: Experiences From Taiwan” published in the Annals of Internal Medicine; 6) “Operational Considerations on the American Academy of Pediatrics Guidance for K-12 School Re-entry” published in JAMA Pediatrics; 7) “Video consultations in primary and specialist care during Covid-19 pandemic and beyond”, published in British Medical Journal; 8) “Managing medication supply chain during the COVID-19 pandemic: Key lessons from Taiwan”, published in Journal of American Pharmacist Association; 9) “An impact oriented approach to epidemiological modeling”, published in Journal for General Internal Medicine; 10) “Influence of Health Beliefs on Adherence to COVID-19 Preventative Practices: an International Social Media–Based Study”, published in Journal of Medical Internet Research; 11) “Considerations and a call to action for the use of noncontact forehead infrared handheld thermometers during the COVID-19 pandemic”, published in J Glob Health; 12) “Contact-tracing app curbs the spread of COVID” published in Nature, and 13) “The Early Detection of Immunoglobulins via Optical-Based Lateral Flow Immunoassay Platform in COVID-19 Pandemic” published in Plos One.

Topic: Recent Advances in Positron Emission Tomography (PET) Technology

Chenming Chang, PhD

Founder and CEO, PETcoil

Abstract:

Medical imaging technologies have revolutionized healthcare. Unlike MRI or X-ray CT, which acquire anatomy, PET measures the distribution of molecular probes, revealing the underlying biology of diseases. PET has broad applications in oncology, cardiology, neurology, infectious diseases, and musculoskeletal diseases. For example, PET has been used to measure the long-term cognitive impairment in COVID-19 patients. In this talk, I will give a brief overview of the recent innovations in PET technology and the emerging applications of PET.

Biography:

Dr. Chenming Chang is the founder and CEO of PETcoil, a startup spun out of Stanford University commercializing a portable positron emission tomography (PET) insert technology for multimodality molecular imaging. Dr. Chang is the principal investigator of a small business research grant sponsored by the National Institutes of Health (NIH) BRAIN Initiative to advance neuroimaging technology. During his Ph.D. training at Stanford University, Dr. Chang led a team of postdocs and graduate students to complete the first radiofrequency field-penetrable PET insert prototype. Dr. Chang holds a master’s degree in Physics from the National Central University and a bachelor’s degree in Physics from the National Tsing Hua University in Taiwan.

Topic: Panel Discussion

Meng-Huang Wu (Max)

Biography:

Meng-Huang Wu (Max) is the vice director of the Prospective Innovation Center at Taipei Medical University Hospital that coordinates innovative initiatives and Chief Executive Officer of Taipei Medical University Biodesign. Max focuses on MedTech innovations and received training in the 2020 Stanford Global Faculty In Training program. Max was in the founding faculty of the Biodesign training program at Taipei Medical University in 2020 and led his team to win first place in the national innovation entrepreneurship competition in He is also a mentor for 500 startups, BE Capital and TMU Biomed Accelerator, that help startups initiate clinical trials in Taiwan. He is a co-host teacher for Biodesign classes at the Artificial Intelligence Medical Research Center and Innovation-Entrepreneur Center, Taipei Medical University.

As an active medical device clinical trial investigator, Max is a committee member of Taipei Medical University’s Joint Institutional Review Board and a seed coordinator for the medical device clinical trial of Taiwan Food and Drug Administration after his training at the Rothman Institute in Philadelphia in 2013. He is also the director of spine division, department of orthopedics at Taipei Medical University Hospital, board director of Taiwan Society of Endoscopic Spine Surgery, Taiwan Society of Minimally Invasive Spine Surgery, Taiwan Medical Design Society, and PhD in Clinical Medical Sciences of Chang-Gung University that experts in bone regeneration, biomaterials, and spinal disorders. He has 47 publications, 2 book chapters, and 8 issued patents. He has collaborated with Industry Technology Research Institution and developed several innovative products including 3D printing sacral plate, 3D printing intervertebral fusion cages, and artificial intelligence spine surgery planning system.

ALBERT YANG

BIOGRAPHY:

Prof. Yang has a background in clinical neuropsychiatry, neuroscience, along with specific training in nonlinear dynamics and biomedical signal analysis acquired at the Margret and H. A. Rey Institute for Nonlinear Dynamics in Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School. Prof. Yang completed residency training in clinical psychiatry at Taipei Veterans General Hospital and is a board-certified psychiatrist in Taiwan for 15 years. Additionally, he has experience in working with biomedical signal analysis, using techniques adapted from physics and nonlinear dynamics, and applies these methods to the study of neurophysiological signals, such as electroencephalogram or resting-state functional MRI signals. These analyses led to the quantification of nonlinear properties of neurophysiological signals for the purpose of investigating the aging and pathophysiology of mental illness. For example, one of the pioneering research led by Dr. Yang was to test the hypothesis pertaining to the loss of brain complexity to explain the psychopathology observed in patients with mental illness. Another major work of Dr. Yang is the new method of quantifying relative causal strength in the mutual causation system with the absence of time precedence. Dr. Yang has published more than 150 peer-reviewed journal publications with an H-index of 42. He is currently the director of Institute of Brain Science as well as Digital Medicine and Smart Healthcare Promotion Center at National Yang-Ming Chiao Tung University, and also serves as the deputy director of medical AI center at Tapei Veterans General Hospital, Taiwan.

Ms.IRENE LEE

BOARD OF DIRECTOR, TAITA-SV

BIOGRAPHY:

Irene Lee is a licensed and registered occupational therapist serving at a public agency located at Santa Clara County, California. She assists students with special needs to be successful in public school system. She is specializedin assistive technology as well as sensory integration. She receives sensory integration certification from University of Southern California.

Irene Lee was an occupational therapist serving at state-level public agency prior to her current position. She has experiences across various practice settings in both public and private agencies as an occupational therapist. She has practiced in inpatient hospital, outpatient clinic, long term care facility and state institute. Prior to becoming an occupational therapist, she was a certified general education teacher in both Taiwan and U.S., and a certified special education teacher in the U.S. She receives her Bachelor of Educationdegree from National Taiwan Normal University, Master of Sciencedegree from Johns Hopkins University, and Master of Occupational Therapy from Loma Linda University.

MS. SANDRA LEE

PRESIDENT , TAITA-SV

BIOGRAPHY:

Sandra Lee is a manager in a hospital system with three main medical centers and twelve clinics. She is experienced in hospital administration, clinical operation, data analysis, strategy planning and medical supply chain. She manages all fixed assets in the hospital system from requisition, approval, procurement, purchasing, inventory to retirement. She also provides data analysis for the hospital supply chain operation.

Prior to her current role, she provided ongoing performance evaluations to support hospital operation needs and to meet changing regulatory agencies standards. She maintained budgeting and staffing portfolio for over 1,400 staffs. She was a liaison between clinics, county, state and federal agencies. Prior to relocating to Bay Area, Sandra was a Senior Analyst at Adventist Health corporate office, which owns 20 acute care hospitals across four states in the U.S. She provided analytical and clinical quality improvement decision supports to various departments across the health system.

Sandra is a licensed and registered pharmacist in Taiwan. She practiced in Taipei Veterans General Hospital and a retail pharmacy as a front line pharmacist. She has solid backgrounds and professional skills in pharmacy, hospital management, operation performance evaluations, clinical quality initiative implementation and medical equipment control. Sandra has a M.S. in Clinical Pharmacy from National Cheng Kung University, a M.P.H from Loma Linda University, and a B.S. in Pharmacy from Taipei Medical University. She is certified in Public Health in U.S.

JOHN HUANG,PH.D

BIOGRAPHY:

John Huang has passionately served the Taiwanese American community in the Bay Area for many years. After receiving his BS from Johns Hopkins University and PhD from the University of Pennsylvania in Biomedical Engineering, he has worked at the medical division of Siemens Medical Systems and later at Abbott Laboratories. His area of expertise is on biosignal processing and automated patient management in ICU.